Venaxis Inc fka APPY

[TheInvincibleBull]

$5.5 & $6 if they break how high can we go??? Loving it

[TheInvincibleBull]

$18.4 mill in assets

[TheInvincibleBull]

Let's break that $5.50

[TheInvincibleBull]

$MGT 5% stake makes me think something big is coming for $APPY just my opinion

[TheInvincibleBull]

3.8mill O/S

[TheInvincibleBull]

Could trade the whole O/S today

[TheInvincibleBull]

Adding more at 5.20 and below ;)

[TheInvincibleBull]

Yep, going to make wild swings already over $1 dip from highs

[TheInvincibleBull]

$5.3's love it

[penny chaser]

Lowest float ive seen

[TheInvincibleBull]

This low of a float heck let's break $10 today

[TheInvincibleBull]

Tiny floater getting wild!!!!

[davidsson10]

8:32 am ET

*MGT Capital Reports 5.01% Stake in Venaxis in 13D(Benzinga)

[TheInvincibleBull]

I love low floaters. Gapping hard going to make nice opportunities on both sides today.

[rudderman]

You could be clearer?

[TheInvincibleBull]

3.8mill o/s this should be fun

[rudderman]

Good morning, someone would know tell me what is causing this rally venaxis title? Is the beginning of a long-term performance or soon return to usual levels?

[Zardiw]

DDAmanda® Chart on: $APPY: Click on the chart twice to see it better.



z

[ClayTrader]

* * $APPY Video Chart 03-16-16 * *

Link to Video - click here to watch the technical chart video

[stocktrademan]

$APPY recent news/filings

bullish 0.2699

## source: finance.yahoo.com

$APPY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$APPY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/APPY/company-info
Ticker: $APPY
OTC Market Place: Not Available
CIK code: 0001167419
Company name: Venaxis, Inc.
Company website: http://www.aspenbioinc.com
Incorporated In: CO, USA

$APPY share structure

## source: otcmarkets.com

Market Value: $6,851,895 a/o Mar 15, 2016
Shares Outstanding: 30,990,029 a/o Aug 11, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$APPY extra dd links

Company name: Venaxis, Inc.
Company website: http://www.aspenbioinc.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/APPY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/APPY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=APPY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=APPY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=APPY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/APPY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/APPY/news - http://finance.yahoo.com/q/h?s=APPY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/APPY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/APPY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/APPY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/APPY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/APPY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/APPY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/APPY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/APPY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=APPY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/APPY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Venaxis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Venaxis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Venaxis%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.aspenbioinc.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.aspenbioinc.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.aspenbioinc.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/APPY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/APPY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/APPY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/APPY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/APPY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001167419&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/APPY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/APPY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/APPY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/APPY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=APPY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=APPY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/APPY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=APPY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=APPY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=APPY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=APPY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=APPY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/APPY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=APPY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/APPY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=APPY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/APPY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/APPY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/APPY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/APPY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/APPY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/APPY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/APPY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=APPY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=APPY



$APPY DD Notes ~ http://www.ddnotesmaker.com/APPY

[RNsidersbuying]

Mr. Lundy continued, "Venaxis is evaluating the alternatives available to it in light of the termination of the Master Agreement and other transaction agreements, and expects to provide an update to its investors as soon as possible."

How bout an update on the delisting status right now? R/S still in the works? What a yoyo!

Appears a great price here trading at 1/2 cash, but this CEO needs to go

[RNsidersbuying]

Wriggled out in the past several days, what a fustercluck this was/IS! Management spent some $18M free cash to buyout a 15-year money sucking loser - oh wait - spent 18M cash to buy only 38% of a money sucking loser?

Projecting this one is off to stinkypinks come the March 8 under$1deadline and a pps dipping well into the .teens, or less, which makes a 10-1 RS much too small to maintain (or more likely attempt to re-establish) a NAZ listing.

Losing some cash on this pos is one thing, but I'll not be losing any more sleep trying to dream up even one positive in this fustercluck of a deal?

[DiscoveryStock]

On top of that, all shorts have to cover when there's a name change.

[RNsidersbuying]

An example: ABC Corp loses $10M in 2015 and gains $10M in 2016 - then the loss would carryover to eliminate the gain for tax purposes. The $10M gain in 2016 would be tax free (approx. $3M tax on $10M profit) using the previous $10M loss as a wash. APPY maintains $102M possible future tax writeoffs on any future profits.

Maybe a poster with more accounting knowledge could expand on my rough numbers?

[DiscoveryStock]

What's the advantage of this, tax credits?

TIA

[dave86]

Less than 6000 dollars traded today.

[cjstocksup]

APPY another nice green day on low volume. Once we get high volume buying pressure on the ask we should see another 50% to 100% day run and I expect it very soon.

[RNsidersbuying]

I'm guessing these sellers have overlooked the accumulated deficit of $102,628,000? What's that worth as a standalone to a 'profitable' company?

At September 30, 2015, the Company had approximate balances of cash and liquid investments of $18,932,000, working capital of $18,278,000, total stockholders' equity of $18,901,000 and an accumulated deficit of $102,628,000.

[cjstocksup]

Yes APPY has great bid support and is red on tiny volume. All we need ahead is buys on the ask.

[dave86]

Am I seeing that right 100,000 on the bid.

[cjstocksup]

APPY news~ Bangalore-based Strand Life Sciences Pvt Ltd, which focuses on clinical genomics and research in biotechnology, is going through a reverse merger with a little-known NASDAQ-listed firm in the second such transaction by an Indian company to go public overseas.

In the process, it will become only the second Indian healthcare and life sciences firm to be listed in the US after drugmaker Dr ....

Read more at:
http://www.vccircle.com/news/pharmaceuticals/2016/01/29/strand-life-sciences-get-listed-nasdaq-through-reverse-merger

[cjstocksup]

APPY ~ CASTLE ROCK, Colo., Jan. 26, 2016 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders. Strand LS is a privately-held, global genomics and bioinformatics company. Strand LS operates clinical reference labs in the US through its wholly owned subsidiary Strand Genomics, Inc., (Strand U.S.) and directly in India, providing testing and lab services in India and other world-wide markets. Strand LS has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.

Assuming participation by 100% of the Strand LS shareholders, the effect of the transaction will be that Strand LS shareholders and the employees and directors who are option-holders in Strand LS will own directly and beneficially approximately 68% of the combined enterprise and the current shareholders of Venaxis will own approximately 32%. Due to Indian tax and financial regulations, the transaction is being structured as purchases, by Venaxis, of the Strand LS shares from the Strand LS shareholders, followed by an immediate re-investment of those sale proceeds, by the Strand LS shareholders, into Venaxis Common Stock.

To comply with certain long-term holding period requirements under Indian tax law, the transaction is expected to be completed in two closings. The first closing will occur upon receipt of the necessary approvals from the Venaxis shareholders, receipt of all other required approvals and satisfaction of identified closing conditions. The second closing will occur approximately six months later. At each closing, Venaxis will enter into resale registration rights agreements with the Strand LS shareholders participating in such closing. The boards of each company have unanimously approved the transaction, however this transaction is subject to Venaxis shareholder approval.

At the first closing, Venaxis will own a majority of the shares of Strand LS, will change its name to Strand Life Sciences, and will change its NASDAQ trading symbol. As part of the first closing, following Venaxis shareholder approval, a Venaxis subsidiary will enter into an asset purchase agreement with Strand U.S. in which it will acquire substantially all of the assets and liabilities of Strand U.S. in exchange for cash consideration paid to Strand U.S.

Advancing to the execution of the agreements with Strand LS, its shareholders and Strand U.S. represents the outcome of an extensive strategic process initiated by Venaxis in early 2015. Venaxis has also commenced, and expects to continue to attempt to locate a partner or other third-party interested in advancing development and or commercial activities of the Venaxis appendicitis portfolio. Aligning Strand Life Sciences' proven technological expertise in genomic profiling, bioinformatics and data curation with Venaxis' financial resources, NASDAQ public listing and key management personnel provides an opportunity for Strand Life Sciences to continue to commercialize its global business model towards what is believed to be a valuable enterprise for the combined shareholders.

Following approval by the Venaxis shareholders and satisfaction of the other closing conditions, at the first closing, Dr. Vijay Chandru, the co-founder and current Executive Chairman of Strand LS, will serve as Executive Chairman of the combined company's Board of Directors, Steve Lundy will become the Chief Executive Officer of the combined company and Jeff McGonegal will continue as CFO. The initial combined board will consist of seven members with four from Strand LS and three from Venaxis.

Commenting on the transaction, Dr. Vijay Chandru said, "On behalf of the Strand LS shareholders, we believe that this transaction represents an attractive opportunity for Strand Life Sciences, as an agile innovator in clinical genomics, to combine forces with Venaxis, a public company in the United States with experienced executives and board members to help it rapidly expand market adoption of StrandAdvantage™ and other future product offerings."

"We are pleased to announce this transaction and are excited by the significant opportunity we believe it presents for shareholders of Venaxis and Strand LS," said Steve Lundy, Chief Executive Officer of Venaxis, Inc. "The combined company will benefit from Strand Life Sciences' 15 year successful history of technological expertise in genomic profiling, bioinformatics and data curation. Our initial focus will be to improve patient outcomes through the use of the StrandAdvantage pan-cancer gene panel, which was commercially launched in the United States in 2015. The combined company is expected to be focused on the continued commercialization of StrandAdvantage, as well as the development of additional oncology-related diagnostics."

Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as joint financial advisors to Strand LS and Baker & Hostetler LLP is acting as legal counsel for Strand LS. Ballard Spahr LLP is acting as legal counsel to Venaxis.

Conference Call
Venaxis and Strand LS will host an investor conference call to discuss the transaction on Wednesday, January 27, 2016, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO of Venaxis, Inc.

[cjstocksup]

Well that is no surprise seekingalpha is usually a rag that runs stocks or shorts stocks to make money off of others. APPY is golden. How could you call PPY one of your top picks for 12016 and sell into a run a day later. The guy is scammer.

[stocking4ms]

I'm holding shares for a long term, can't say the same about Daniel.
Stocktwits: Daniel_Ward, 1/27 around 10.12 am
"Decided to exit my $APPY a little over $0.32. Reasons:
1. Strand's business is not my knowledge expertise.
2. Merger length...
3. I don’t want to own Theranos secondary play.
4. Not announcing more investors committing funds is odd.
5. I want cash to reinvest in this environment. Best of luck to those continuing as investors in the new company."

[cjstocksup]

APPY should be running back over the 50 and 200 day MA's very soon!

[$Pistol Pete$]

$APPY Daily and Weekly Charts

[BAD HEMPER]

The Dow is screaming upward. We should be moving too.

[cjstocksup]

Nothing but mirror trades meaning naked shorts. Crazy IMO ahead of next week.

[BAD HEMPER]

Strong merger news again and a decent valuation and we could run for days

[cjstocksup]

Daniel called it~ APPY gets a nod from Daniel Ward at seekingalpha as one of the top biotech picks for 2016:

Venaxis (NASDAQ:APPY) - 15% Allocation: Venaxis is a new name to my Top Value Biotechs list. Venaxis is an in vitro diagnostic company developing and commercializing its unique multi-biomarker diagnostic test, the APPY1 test. While the name popped 50% within a few days after I initially discussed it in a spotlight piece back in April, the name has lagged since. When I wrote about the name in late July, I expected the company to would likely follow up with a Q3 business update on the path forward with APPY1, but the company has been extremely quiet. Two main points I would like to highlight are as follows:

1. Sale of Headquarters: The only piece of news that has come out since the last business update in late June is the fact that the company sold its corporate headquarters in Castle Rock, Colorado. The company announced through the 8-K filed on October 21st that it sold its headquarters to Niebur Golf Development, LLC for $4,053,000 with closing expected to take place in December. The company expects to generate $1.7 million in net cash from this sale after expenses and mortgage payoffs. Post-closing the company will just pay a lease payment of $22,000 per month. Why would a company sell its headquarters? The sale cleans up the balance sheet in that the company will get $990,500 in cash at close and will receive a note receivable for the remainder of money owed. The company can pay off debt and is now only committed to a lease that can be ended with 60 days' notice with the ability to provide notice starting January 31.

2. What is Going on at Venaxis?: Other than the sale of the headquarters, news has been nonexistent. Let's think critically about the one piece of news we have gotten. Cleaning up the balance sheet by taking care of selling the company's main property and equipment is something I view as preparing the company for a strategic action. Additionally supporting this line of thinking is the fact that the company has not had a business update call for six months, which is unheard of and signals to me that they are in the process of a substantial strategic action. Even when considering cash burn of $1.35 million per quarter (the level of cash burn management has guided previously) or even cash burn up to $2.00 million given that we are generally unsure what exactly the company is doing, cash at year end would still likely be between $16.9 and $17.6 million based on the Q3 end cash balance. Adding the $990,500 in upfront cash from the real estate deal would bring this cash estimate up to between $17.9 and $18.6 million. The company may use some of the cash to pay off the mortgage note, but this would not affect shareholder equity. Shareholder equity was $18.9 million as of Q3 end. Based on a market cap of only $9.6 million, the stock currently trades at only 0.5x-0.6x based on book value and cash value. Way back in the June 2015 business update, the company had noted it was reviewing a variety of business opportunities. While I had initially thought the company would just be doing an asset buy in the in-vitro diagnostics space, the company's more or less silence over the past 6 months makes me think they could be reviewing a more substantial strategic action like a reverse merger. If the company were just looking at a more minor strategic action, I would expect them to keep investors much more updated on what was going on with other parts of the business like APPY1 and APPY2.

Concluding Thoughts On Venaxis: Ultimately, given the lack of communication with shareholders, it's hard to predict exactly what is happening at Venaxis. While I think the sale of the headquarters combined with the company dropping off the radar in terms of updates for six months means that the company may be completing a more substantial strategic alternative (such as a reverse merger) that was identified through the business development review, I want to acknowledge that this is merely conjecture as there are a wide variety of things that could be going on at Venaxis. While I do think we may very well see a strategic alternative, it's also possible that the next update brings disappointment in terms of lack of progress with APPY1 and APPY2. With the stock trading at 0.5x-0.6x book and roughly the same ratio based on cash, I think downside is muted though given the balance sheet even if the company provides a disappointing, lackluster update.

http://seekingalpha.com/article/3779066-biotech-weekly-top-value-biotech-picks-for-2016

[cjstocksup]

APPY ran on news of the thought of the Stand merger to .37 here is the chart imagine what we can do next week!
http://stockcharts.com/h-sc/ui?s=appy

[cjstocksup]

LMAO no one even knows about this yet. Next week should be fun $$$ for APPY shareholders!

[dave86]

Hopefully this merger gives me a nice trading account to have finally lol

[cjstocksup]

Someone posted them during the last news run and they were awesome. We all figured a couple bucks a share on the APPY merger with Strand.

[cjstocksup]

Wondered why PHLX and EDGA were on the APPY bid all morning taking any shares they could only showing 100 shares yet they absorbed anything that hit them without having to chase above. Let the chase begin. Next week should be fun.

[dave86]

Mine too =)

[dave86]

I wonder what Strand financials look like.

[cjstocksup]

Yep someone is doing a small APPY share exchange down here before the big merger news hit's IMO.

[BAD HEMPER]

Sounds good

[cjstocksup]

I had mine at $1.00 on all my accounts with APPY I am moving them up to $3.00 for now.